Investigating the Effects of BIBR1532 and Related Analogs on Telomerase Activity in Human Prostate Cancer Cells

Presentation Type

Poster/Portfolio

Presenter Major(s)

Cell and Molecular Biology

Mentor Information

Suganthi Sridhar

Department

Biomedical Sciences

Location

Henry Hall Atrium 60

Start Date

11-4-2012 9:00 AM

Keywords

Health, Life Science

Abstract

Unlimited cellular proliferation of cancer cells is coupled with the maintenance of telomeres in DNA. Telomerase, the enzyme that re-extends telomeres, has become an attractive target for new cancer therapeutics. BIBR1532, a mixed-type non-competitive inhibitor of telomerase, has been shown to cause growth arrest in tumor cells. Here, we tested BIBR1532 and two synthetic analogues (WS6-48, WS4-43A) for anti-proliferative activity on metastatic prostate cancer cells. Preliminary results indicate these compounds are highly active against proliferation. Their effects on inhibiting telomerase activity directly were quantified using a telomere repeat amplification protocol assay. Newly developed analogues are under preliminary testing to determine their effect upon telomerase. Available x-ray structures of telomerase domains are also being explored to asses ligand binding sites and affinities. Further studies will asses the effect these compounds have on other metastatic cancer cell lines.

This document is currently not available here.

Share

COinS
 
Apr 11th, 9:00 AM

Investigating the Effects of BIBR1532 and Related Analogs on Telomerase Activity in Human Prostate Cancer Cells

Henry Hall Atrium 60

Unlimited cellular proliferation of cancer cells is coupled with the maintenance of telomeres in DNA. Telomerase, the enzyme that re-extends telomeres, has become an attractive target for new cancer therapeutics. BIBR1532, a mixed-type non-competitive inhibitor of telomerase, has been shown to cause growth arrest in tumor cells. Here, we tested BIBR1532 and two synthetic analogues (WS6-48, WS4-43A) for anti-proliferative activity on metastatic prostate cancer cells. Preliminary results indicate these compounds are highly active against proliferation. Their effects on inhibiting telomerase activity directly were quantified using a telomere repeat amplification protocol assay. Newly developed analogues are under preliminary testing to determine their effect upon telomerase. Available x-ray structures of telomerase domains are also being explored to asses ligand binding sites and affinities. Further studies will asses the effect these compounds have on other metastatic cancer cell lines.